{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:47:53Z","timestamp":1792277273934,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.anndiagpath.2020.151622","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T11:21:55Z","timestamp":1599477715000},"page":"151622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome"],"prefix":"10.1016","volume":"49","author":[{"given":"Diana","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Glisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randal","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2020.151622_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/era.13.1","article-title":"Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers","volume":"13","author":"Bell","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11912-019-0776-4","article-title":"Sinonasal undifferentiated carcinoma","volume":"21","author":"Abdelmeguid","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/PAP.0000000000000258","article-title":"Sinonasal undifferentiated carcinoma (SNUC): from an entity to morphologic pattern and back again-a historical perspective","volume":"27","author":"Agaimy","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hed.21830","article-title":"Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data","volume":"34","author":"Turner","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0025","series-title":"WHO classification of head and neck tumours","author":"El-Naggar","year":"2017"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00000478-198611000-00004","article-title":"Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma","volume":"10","author":"Frierson","year":"1986","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0035","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.18.00353","article-title":"Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma","volume":"37","author":"Amit","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0040","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1055\/s-0034-1390014","article-title":"Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment","volume":"18","author":"Su","year":"2014","journal-title":"Int Arch Otorhinolaryngol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.semdp.2015.12.001","article-title":"Recently described neoplasms of the sinonasal tract","volume":"33","author":"Bishop","year":"2016","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0050","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/PAS.0000000000000285","article-title":"SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract","volume":"38","author":"Bishop","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergencyto.2010.06.007","article-title":"NUT midline carcinoma","volume":"203","author":"French","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pin.12727","article-title":"NUT carcinoma: clinicopathologic features, pathogenesis, and treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol Int"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12105-018-0887-5","article-title":"Sinonasal neuroendocrine neoplasms: current challenges and advances in diagnosis and treatment, with a focus on olfactory neuroblastoma","volume":"12","author":"Bell","year":"2018","journal-title":"Head Neck Pathol"},{"issue":"Suppl. 1","key":"10.1016\/j.anndiagpath.2020.151622_bb0070","first-page":"E2259","article-title":"Neuroendocrine neoplasms of the sinonasal region","volume":"38","author":"Bell","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0075","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/hed.21940","article-title":"Multimodality treatment for sinonasal neuroendocrine carcinoma","volume":"34","author":"Mitchell","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0080","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/cncr.20693","article-title":"Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype","volume":"101","author":"Rosenthal","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0085","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000001508","article-title":"Recurrent loss of SMARCA4 in sinonasal teratocarcinosarcoma","author":"Rooper","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0090","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1158\/1078-0432.CCR-12-1876","article-title":"Establishment and characterization of novel cell lines from sinonasal undifferentiated carcinoma","volume":"18","author":"Takahashi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fcell.2019.00052","article-title":"Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy","volume":"7","author":"Canning","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0100","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/2326-6066.CIR-17-0112","article-title":"Human tumor antigens yesterday, today, and tomorrow","volume":"5","author":"Finn","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101396","article-title":"Introduction to the special issue: tumor antigens in the time of the coronavirus pandemic","volume":"47","author":"Finn","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2020.01.001","article-title":"Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: correlation of the quality of T cell responses with NSCLC subtype","volume":"219","author":"Palata","year":"2020","journal-title":"Immunol Lett"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.oraloncology.2019.02.003","article-title":"A functional gene expression analysis in epithelial sinonasal cancer: biology and clinical relevance behind three histological subtypes","volume":"90","author":"De Cecco","year":"2019","journal-title":"Oral Oncol"},{"issue":"Suppl. 8","key":"10.1016\/j.anndiagpath.2020.151622_bb0125","doi-asserted-by":"crossref","first-page":"viii6","DOI":"10.1093\/annonc\/mds256","article-title":"Immuno-oncology: understanding the function and dysfunction of the immune system in cancer","volume":"23","author":"Finn","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4049\/jimmunol.1701302","article-title":"A believer\u2019s overview of cancer immunosurveillance and immunotherapy","volume":"200","author":"Finn","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070984","article-title":"Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME?","volume":"11","author":"Al-Khadairi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-016-0020-7","article-title":"The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions","volume":"11","author":"Cai","year":"2016","journal-title":"Cell Div"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.critrevonc.2011.12.005","article-title":"Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials","volume":"83","author":"De Pas","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0155","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol Invest"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2443.2007.01146.x","article-title":"Mash1 is required for neuroendocrine cell development in the glandular stomach","volume":"13","author":"Kokubu","year":"2008","journal-title":"Genes Cells"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0165","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00418-020-01863-z","article-title":"Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells","volume":"153","author":"Kudoh","year":"2020","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0170","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.humpath.2012.11.013","article-title":"Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases","volume":"44","author":"La Rosa","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.anndiagpath.2015.03.009","article-title":"Achaete-scute homolog 1 expression closely correlates with endocrine phenotype and degree of differentiation in sinonasal neuroendocrine tumors","volume":"19","author":"Taggart","year":"2015","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5858\/arpa.2015-0489-OA","article-title":"mASH1 is highly specific for neuroendocrine carcinomas: an immunohistochemical evaluation on normal and various neoplastic tissues","volume":"141","author":"Altree-Tacha","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0185","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/modpathol.3800038","article-title":"hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors","volume":"17","author":"Jiang","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0190","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jcp.10290","article-title":"MHC class I antigens, immune surveillance, and tumor immune escape","volume":"195","author":"Garcia-Lora","year":"2003","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0200","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/1547691X.2013.875084","article-title":"The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors","volume":"11","author":"Seliger","year":"2014","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0205","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4161\/onci.21205","article-title":"Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy","volume":"1","author":"Thibodeau","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013101061","article-title":"CXCL5 drives neutrophil recruitment in TH17-mediated GN","volume":"26","author":"Disteldorf","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.intimp.2017.08.012","article-title":"CCL28 chemokine: an anchoring point bridging innate and adaptive immunity","volume":"51","author":"Mohan","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0220","first-page":"585","article-title":"Down-regulation of DMBT1 gene expression in human oral squamous cell carcinoma","volume":"15","author":"Imai","year":"2005","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0225","first-page":"1704","article-title":"DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer","volume":"60","author":"Mollenhauer","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bjc.6690035","article-title":"Lack of DMBT1 expression in oesophageal, gastric and colon cancers","volume":"79","author":"Mori","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0235","first-page":"1846","article-title":"Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer","volume":"59","author":"Wu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0240","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/CCO.0000000000000390","article-title":"Targeting EZH2 in cancer therapy","volume":"29","author":"Yamagishi","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061172","article-title":"EZH2 in cancer progression and potential application in cancer therapy: a friend or foe?","volume":"18","author":"Yan","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0250","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0260","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","article-title":"PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification","volume":"53","author":"Langelier","year":"2018","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.anndiagpath.2020.151622_bb0270","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and immune-checkpoint inhibitor combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913420301684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913420301684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:32:40Z","timestamp":1761078760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913420301684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":54,"alternative-id":["S1092913420301684"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151622","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151622"}}